Consumption of Whole Grains and Legumes Modulates the Genetic Effect of the APOA5 -1131C Variant

Yonsei University200 enrolled

Overview

We examined whether a substitution of whole grains and legumes for refined rice in a high carbohydrate diet (about 65% of energy derived from carbohydrate) may modify the effect of this variant on changes in apolipoprotein A-V (apoA-V) and triglyceride concentrations.

We genotyped the APOA5 -1131T\>C in individuals with impaired fasting glucose (IFG) or newly diagnosed type 2 diabetes, who were randomly assigned to either a group ingesting whole grain and legume meals daily or a control group for 12 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

200

Conditions

Subjects With Mild Hypertriglyceridemia in Type 2 DM

Interventions

Dietary interventionDIETARY_SUPPLEMENT

The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.

Eligibility

Sex: ALLMin age: 25 YearsMax age: 72 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who were in in impaired fasting glucose (IFG, 100≤ fasting glucose \<126 mg/dL) and newly diagnosed type 2 diabetes (fasting glucose ≥126 mg/dL) were referred to the Department of Family Medicine or Internal Medicine. They were rechecked for their health and lipid profiles, and then those who satisfied the study criteria were recommended to participate in the dietary intervention program Exclusion Criteria: * Current and/or past history of cardiovascular disease including angina * Liver or kidney dysfunction * Thyroid or pituitary disease * Unstable weight loss/gain (≥2 kg) over the previous 6months * Pregnancy or lactation. Subjects who were taking medication were also excluded

Locations (1)

Yonsei university

Seoul, South Korea

Outcomes

Primary Outcomes

Triglyceride

Time frame: change from baseline in TG at 12 weeks

Secondary Outcomes

Apolipoprotein A5

Time frame: Change from baseline in ApoA5 at 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.